## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.2% below STRENGTH zone (3.0-6.0%); PEG 1.07 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($35.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Invesco Ltd. Purchases 633,946 Shares of Centene Corporation $CNC**
- Source: MarketBeat | 20251204T120816 | Neutral | Relevance: 98%
- Invesco Ltd. increased its holdings in Centene Corporation by 5.7%, acquiring an additional 633,946 shares, bringing its total ownership to 11,725,910 shares valued at approximately $636.5 million. Centene reported strong Q3 earnings, beating analyst expectations with $0.50 EPS and $49.69 billion in revenue, showing an 18.2% year-over-year revenue increase. The company currently holds an average analyst "Hold" rating with a consensus target price of $40.00.

**2. Sio Capital Management LLC Takes Position in Centene Corporation $CNC**
- Source: MarketBeat | 20251204T041007 | Neutral | Relevance: 97%
-  Sio Capital Management LLC has acquired a new position of 262,500 shares in Centene Corporation ($CNC) during the second quarter, valued at approximately $14.25 million, making it their fourth-largest holding. Centene exceeded earnings expectations with $0.50 EPS against a ($0.21) consensus and revenue of $49.69 billion. Despite a negative net margin, analysts currently rate the stock as "Hold" with a consensus price target of $40.00.

**3. Hereâ€™s Why Centene Corporation (CNC) Reduced Its Earnings Outlook**
- Source: MSN | 20251204T060818 | Neutral | Relevance: 97%
- Centene Corporation (CNC) has reduced its earnings outlook, leading to investor concern. This revision often indicates challenges in operations or market conditions that impact the company's profitability. Analysts and investors will closely monitor Centene's future reports for further insights into its performance.

**4. Centene director Burdick sells $2.57 million in stock**
- Source: Investing.com India | 20251205T224551 | Neutral | Relevance: 97%
-  Centene director Kenneth A. Burdick recently sold 65,907 shares of common stock for approximately $2.57 million in two transactions. Despite this sale, Centene has a strong free cash flow yield of 18% and management is aggressively buying back shares. The company has also announced significant expansion of its Medicare Advantage plans and reported strong adjusted earnings per share for Q3 2025.

**5. Guidance Cut From Higher Exchange Costs Could Be A Game Changer For Centene (CNC)**
- Source: Simply Wall Street | 20251204T200857 | Neutral | Relevance: 97%
-  Centene (CNC) has cut its earnings guidance due to higher-than-expected medical utilization in its federal exchange plans and ongoing pressure in its Medicaid business. This adjustment raises concerns that potential changes to federal exchange subsidy policy could lead to a smaller, sicker enrollee base, putting additional pressure on profitability and reshaping Centene's investment narrative. The company's updated 2025 outlook now anticipates a GAAP diluted loss per share not exceeding US$12.85, impacting its short-term earnings recovery prospects.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |
| 2025-11-12 | Wells Fargo | $35 | $41 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |
| 2025-11-12 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Long-term trend broken: trading 13.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Forward P/E 13.1x attractive for 46% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.7B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 13.1 |
| Current P/E | 19.2 |
| YoY Growth | 46.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 5.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.23% (CS: 30) | Weak |
| RSI_14 | 55.4 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 1.027x | Above |
| vs SMA50 | 1.050x | Above |
| vs SMA200 | 0.863x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $38.34
- **Stop Loss:** $35.44 (7.6% risk)
- **Target:** $41.24 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 172
- **Position Value:** $6,594.48
- **Portfolio %:** 6.59%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*